Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
BUSINESS
All 11 Manufacturers Pull Ranitidine from Shelves, “Class I” Recalls for 9 Firms
All 11 manufacturing authorization holders of ranitidine-contained drugs in Japan have now launched voluntary recalls for their products over their potential contamination with a cancer-causing impurity called N-nitrosodimethylamine (NDMA), with nine of them having issued most-urgent “Class I” recalls by…
To read the full story
Related Article
- Zeria’s Acinon Now Sole Nizatidine Product Being Shipped as Yoshindo Launches Recall
January 13, 2023
- Man Sues PMDA over Rejected Relief Claim for “Ranitidine Caused Cancer”
December 7, 2022
- All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
- Drug Makers Moving to Discontinue Ranitidine/Nizatidine Products over Carcinogen Issue
February 4, 2021
- ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials
January 24, 2020
- Original Maker Recalls Nizatidine over Carcinogen Risks
December 4, 2019
- Ohara Launches Class I Recall for Nizatidine over Carcinogen Risks
October 24, 2019
- JMA Chides MHLW for Information Provisioning on Cefazolin Shortage
October 18, 2019
- Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
October 17, 2019
- GSK Japan to Pull Prescribed Zantac and Compensate for Substitutes; Generic Peers Follow
October 11, 2019
- GSK Japan Ups Recall Level for Zantac to “Class I”
October 10, 2019
- GSK Recalls Zantac as Preventive Measure for NDMA Carcinogenic Risk
September 30, 2019
- MHLW Asks 15 Makers to Investigate Ranitidine, Nizatidine for Potential Carcinogen Contamination
September 20, 2019
BUSINESS
- Takeda Puts Up 100 Billion Yen for New Plasma Therapy Facility in Japan
March 24, 2023
- Ono, Kasawaki-Based AI Platform Firm Tie Up on Antibody Drug Discovery
March 24, 2023
- Hutchmed’s Colorectal Cancer Med Logs Positive Data in Japanese Cohort: Takeda
March 24, 2023
- Ono, Macomics Ink Macrophage Drug Discovery Deal
March 24, 2023
- Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
March 24, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…